Chuling Fang1, Hui Huang1, Qian Zhang1, Na Wang1, Xiaoyan Jing1, Jian Guo1, Martin Ferianc2, Zuojun Xu1. 1. Department of Respiratory and Critical Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. 2. Electronic and Electrical Engineering Department, University College London, London, UK.
Abstract
BACKGROUND AND OBJECTIVE: IPF is an ageing-related lung disorder featuring progressive lung scarring. IPF patients are frequently identified with short telomeres but coding mutations in telomerase can only explain a minority of cases. Sex hormones regulate telomerase activity in vitro and levels of sex hormones are related to LTL. The objective of this study was to explore whether sex hormones were associated with LTL, whether they interacted with genetic variants in telomerase and whether polymorphisms in the exon of androgen metabolism genes were associated with plasma testosterone concentrations in male IPF patients. METHODS: A case-control study was performed on 101 male IPF subjects and 51 age-matched healthy controls. Early morning plasma sex hormones were quantified, and whole-exome sequencing was used to identify rare protein-altering variants of telomerase and SNP in the exon of androgen metabolism genes. LTL was analysed by PCR and expressed as a T/S ratio. RESULTS: LTL, testosterone and DHT were decreased significantly in the IPF group. After adjustments for age and variant status in telomerase-related genes, only testosterone was positively associated with LTL (P = 0.001). No significant interaction (P = 0.661) was observed between rare protein-altering variants of telomerase and testosterone. No coding SNP in androgen metabolism genes were significantly associated with testosterone concentrations. CONCLUSION: Plasma testosterone is associated with LTL independent of age or rare protein-altering variants of telomerase. No genetic variations of androgen-related pathway genes are associated with androgen concentrations. Further studies are warranted to examine whether hormonal interventions might retard telomere loss in male IPF patients.
BACKGROUND AND OBJECTIVE: IPF is an ageing-related lung disorder featuring progressive lung scarring. IPF patients are frequently identified with short telomeres but coding mutations in telomerase can only explain a minority of cases. Sex hormones regulate telomerase activity in vitro and levels of sex hormones are related to LTL. The objective of this study was to explore whether sex hormones were associated with LTL, whether they interacted with genetic variants in telomerase and whether polymorphisms in the exon of androgen metabolism genes were associated with plasma testosterone concentrations in male IPF patients. METHODS: A case-control study was performed on 101 male IPF subjects and 51 age-matched healthy controls. Early morning plasma sex hormones were quantified, and whole-exome sequencing was used to identify rare protein-altering variants of telomerase and SNP in the exon of androgen metabolism genes. LTL was analysed by PCR and expressed as a T/S ratio. RESULTS:LTL, testosterone and DHT were decreased significantly in the IPF group. After adjustments for age and variant status in telomerase-related genes, only testosterone was positively associated with LTL (P = 0.001). No significant interaction (P = 0.661) was observed between rare protein-altering variants of telomerase and testosterone. No coding SNP in androgen metabolism genes were significantly associated with testosterone concentrations. CONCLUSION: Plasma testosterone is associated with LTL independent of age or rare protein-altering variants of telomerase. No genetic variations of androgen-related pathway genes are associated with androgen concentrations. Further studies are warranted to examine whether hormonal interventions might retard telomere loss in male IPFpatients.
Authors: Rodrigo T Calado; William T Yewdell; Keisha L Wilkerson; Joshua A Regal; Sachiko Kajigaya; Constantine A Stratakis; Neal S Young Journal: Blood Date: 2009-06-26 Impact factor: 22.113
Authors: Mary Y Armanios; Julian J-L Chen; Joy D Cogan; Jonathan K Alder; Roxann G Ingersoll; Cheryl Markin; William E Lawson; Mingyi Xie; Irma Vulto; John A Phillips; Peter M Lansdorp; Carol W Greider; James E Loyd Journal: N Engl J Med Date: 2007-03-29 Impact factor: 91.245
Authors: Amy Dressen; Alexander R Abbas; Christopher Cabanski; Janina Reeder; Thirumalai R Ramalingam; Margaret Neighbors; Tushar R Bhangale; Matthew J Brauer; Julie Hunkapiller; Jens Reeder; Kiran Mukhyala; Karen Cuenco; Jennifer Tom; Amy Cowgill; Jan Vogel; William F Forrest; Harold R Collard; Paul J Wolters; Jonathan A Kropski; Lisa H Lancaster; Timothy S Blackwell; Joseph R Arron; Brian L Yaspan Journal: Lancet Respir Med Date: 2018-06-18 Impact factor: 30.700
Authors: Jonathan K Alder; Julian J-L Chen; Lisa Lancaster; Sonye Danoff; Shu-chih Su; Joy D Cogan; Irma Vulto; Mingyi Xie; Xiaodong Qi; Rubin M Tuder; John A Phillips; Peter M Lansdorp; James E Loyd; Mary Y Armanios Journal: Proc Natl Acad Sci U S A Date: 2008-08-27 Impact factor: 11.205
Authors: Nevins W Todd; Sergei P Atamas; Stella E Hines; Irina G Luzina; Nirav G Shah; Edward J Britt; Andrew J Ghio; Jeffrey R Galvin Journal: Expert Rev Respir Med Date: 2022-01-31 Impact factor: 3.772
Authors: John A Mackintosh; Maria Pietsch; Viviana Lutzky; Debra Enever; Sandra Bancroft; Simon H Apte; Maxine Tan; Stephanie T Yerkovich; Joanne L Dickinson; Hilda A Pickett; Hiran Selvadurai; Christopher Grainge; Nicole S Goh; Peter Hopkins; Ian Glaspole; Paul N Reynolds; Jeremy Wrobel; Adam Jaffe; Tamera J Corte; Daniel C Chambers Journal: BMJ Open Respir Res Date: 2021-12